Literature DB >> 7890216

Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.

S H Hussaini1, S P Pereira, G M Murphy, C Kennedy, J A Wass, G M Besser, R H Dowling.   

Abstract

Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients. Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones. Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight. In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones). Gall bladder bile was obtained by ultrasound guided, fine needle puncture from six patients. All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling. Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up. After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich. This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%). In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890216      PMCID: PMC1382366          DOI: 10.1136/gut.36.1.126

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Comparison of gall bladder bile and endoscopically obtained duodenal bile.

Authors:  P Janowitz; W Swobodnik; J G Wechsler; A Zöller; K Kuhn; H Ditschuneit
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

2.  Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates.

Authors:  P J Thomas; A F Hofmann
Journal:  Gastroenterology       Date:  1973-10       Impact factor: 22.682

3.  Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy.

Authors:  J R Walters; K A Hood; D Gleeson; J P Ellul; A Keightley; G M Murphy; R H Dowling
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

4.  Computed tomography in predicting gall stone solubility: a prospective trial.

Authors:  A Caroli; G Del Favero; F Di Mario; F Spigariol; P Scalon; T Meggiato; C Zambelli; R Naccarato
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 5.  Gallstones during octreotide therapy.

Authors:  R H Dowling; S H Hussaini; G M Murphy; G M Besser; J A Wass
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

6.  [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].

Authors:  L E Buscail; C Puel-Bousquet; A G Harris; J P Tauber; J R Escourrou; M M Delvaux; N M Vaysse; F Bayard; A Ribet
Journal:  Gastroenterol Clin Biol       Date:  1991

7.  Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.

Authors:  S M Catnach; J V Anderson; P D Fairclough; R C Trembath; P A Wilson; E Parker; G M Besser; J A Wass
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

8.  Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man.

Authors:  R T Holzbach; M Marsh; M Olszewski; K Holan
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

9.  The physicochemical basis of cholesterol gallstone formation in man.

Authors:  W H Admirand; D M Small
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

10.  Diagnostic fine-needle puncture of the gallbladder with US guidance.

Authors:  W Swobodnik; N Hagert; P Janowitz; H Wenk
Journal:  Radiology       Date:  1991-03       Impact factor: 11.105

View more
  10 in total

Review 1.  Management and Complications of Short Bowel Syndrome: an Updated Review.

Authors:  Robert E Carroll; Enrico Benedetti; Joseph P Schowalter; Alan L Buchman
Journal:  Curr Gastroenterol Rep       Date:  2016-07

2.  Successful treatment of congenital chylous ascites with a somatostatin analogue.

Authors:  M G Caty; M L Hilfiker; R G Azizkhan; P L Glick
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

3.  Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones.

Authors:  A F Hofmann
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

4.  Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly.

Authors:  L A Thomas; M J Veysey; G M Murphy; D Russell-Jones; G L French; J A H Wass; R H Dowling
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

Authors:  R Attanasio; A Mainolfi; F Grimaldi; R Cozzi; M Montini; C Carzaniga; S Grottoli; L Cortesi; M Albizzi; R M Testa; L Fatti; D De Giorgio; C Scaroni; F Cavagnini; P Loli; G Pagani; E Ghigo
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 6.  Epidemiology, management, and economic evaluation of screening of gallstone disease among type 2 diabetics: A systematic review.

Authors:  Lujie Chen; Yu-Ting Peng; Fu-Li Chen; Tao-Hsin Tung
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

7.  Gallstone disease: current therapeutic practice.

Authors:  Chad I Williams; Eldon A Shaffer
Journal:  Curr Treat Options Gastroenterol       Date:  2008-04

8.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

9.  Incidence of gall stone formation in acromegalic patients on octreotide therapy.

Authors:  Aditi A Chakravarty; Ajay Ajmani; Smita Manchanda; Bindu Kulshreshtha; Shweta Chopra
Journal:  Indian J Endocrinol Metab       Date:  2012-05

Review 10.  An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Genes (Basel)       Date:  2020-11-29       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.